Author:
Gentiluomo Manuel,Corradi Chiara,Vanella Giuseppe,Johansen Astrid Z.,Strobel Oliver,Szentesi Andrea,Milanetto Anna Caterina,Hegyi Péter,Kupcinskas Juozas,Tavano Francesca,Neoptolemos John P.,Bozzato Dania,Hackert Thilo,Pezzilli Raffaele,Johansen Julia S.,Costello Eithne,Mohelnikova-Duchonova Beatrice,van Eijck Casper H. J.,Talar-Wojnarowska Renata,Hansen Carsten Palnæs,Darvasi Erika,Chen Inna M.,Cavestro Giulia Martina,Soucek Pavel,Piredda Liliana,Vodicka Pavel,Gazouli Maria,Arcidiacono Paolo Giorgio,Canzian Federico,Campa Daniele,Capurso Gabriele
Abstract
AbstractAlthough pancreatic ductal adenocarcinoma (PDAC) survival is poor, there are differences in patients’ response to the treatments. Detection of predictive biomarkers explaining these differences is of the utmost importance. In a recent study two genetic markers (CD44-rs353630 and CHI3L2-rs684559) were reported to be associated with survival after PDAC resection. We attempted to replicate the associations in 1856 PDAC patients (685 resected with stage I/II) from the PANcreatic Disease ReseArch (PANDoRA) consortium. We also analysed the combined effect of the two genotypes in order to compare our results with what was previously reported. Additional stratified analyses considering TNM stage of the disease and whether the patients received surgery were also performed. We observed no statistically significant associations, except for the heterozygous carriers of CD44-rs353630, who were associated with worse OS (HR = 5.01; 95% CI 1.58–15.88; p = 0.006) among patients with stage I disease. This association is in the opposite direction of those reported previously, suggesting that data obtained in such small subgroups are hardly replicable and should be considered cautiously. The two polymorphisms combined did not show any statistically significant association. Our results suggest that the effect of CD44-rs353630 and CHI3L2-rs684559 cannot be generalized to all PDAC patients.
Funder
Italian Ministry of Health
Ministerstvo Zdravotnictví Ceské Republiky
Associazione Italiana per la Ricerca sul Cancro
Fondazione Arpa
Fondazione Tizzi
Publisher
Springer Science and Business Media LLC
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献